Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Acquisitions (2016 - 2018)

Myriad Genetics (MYGN) has disclosed Acquisitions for 4 consecutive years, with -$1.1 million as the latest value for Q4 2018.

  • Quarterly Acquisitions changed N/A to -$1.1 million in Q4 2018 from the year-ago period, while the trailing twelve-month figure was -$1.1 million through Dec 2020, changed N/A year-over-year, with the annual reading at $57.2 million for FY2022, N/A changed from the prior year.
  • Acquisitions for Q4 2018 was -$1.1 million at Myriad Genetics, down from $279.6 million in the prior quarter.
  • The five-year high for Acquisitions was $279.6 million in Q3 2018, with the low at -$1.1 million in Q4 2018.
  • Average Acquisitions over 3 years is $98.9 million, with a median of $3.1 million recorded in 2016.